BioCancell Therapeutics Announces Success in Phase I/IIa Pancreatic Cancer Clinical Trial  
11/1/2010 11:42:47 AM

JERUSALEM--(BUSINESS WIRE)--Success for biopharmaceutical company BioCancell (TASE:BICL): BioCancell, a developer of anti-cancer drugs, announced success in attaining the goals of its Phase I/IIa clinical trial of BC-819 as a treatment for pancreatic cancer, which demonstrated an excellent safety profile and preliminary efficacy. The primary endpoint, drug safety, was achieved with no side effects definitely connected to BC-819, and no patients complaining about pain or discomfort as a result of the drug.